Stay updated with breaking news from Azenta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysts expect that Azenta, Inc. (NASDAQ:AZTA – Get Rating) will post $141.73 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Azenta’s earnings, with the lowest sales estimate coming in at $140.58 million and the highest estimate coming in at $142.60 million. Azenta reported sales of $286.59 […]
/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has rescheduled the release of its earnings for the second fiscal quarter of 2022 which...
Azenta (NASDAQ:AZTA – Get Rating) and Katy Industries (OTCMKTS:KATYQ – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Institutional & Insider Ownership 92.9% of Azenta shares are owned by […]
/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal 2022 second quarter earnings which ended on March 31, 2022 on Tuesday, May 3, 2022 after the...
Azenta (NASDAQ:AZTA – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Azenta Inc. is a provider of life sciences solutions. The company provides reliable cold-chain sample management solutions and genomic services across areas […]